TY - JOUR
T1 - Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries
AU - Tamez, Hector
AU - Secemsky, Eric A.
AU - Valsdottir, Linda R.
AU - Moussa, Issam D.
AU - Song, Yang
AU - Simonton, Charles A.
AU - Gibson, C. Michael
AU - Popma, Jeffrey J.
AU - Yeh, Robert W.
N1 - Funding Information:
This study was funded by an investigator-initiated grant from Abbott Vascular.
Funding Information:
E.A. Secemsky reports grants/personal fees from Medtronic, CSI, Boston Scientific, Philips, Cook Medical, BD Bard, AstraZeneca, Janssen. C.A. Simonton is a former employee of Abbott Vascular, and an employee of Abiomed. C.M. Gibson received research support and consultant fees from Janssen Pharmaceuticals, Johnson and Johnson, Bayer, and Portola, as well as research support from the Baim Institute for Clinical Research. J.J. Popma is an employee of Medtronic and is not affiliated with Beth Israel Deaconess Medical Center. He reports grants from Medtronic, Boston Scientific, Abbott, and Edwards Lifesciences. R.W. Yeh received a research grant, consulting, and advisory board fees from Abbott Vascular, Boston Scientific, and Medtronic. The other authors have no conflicts of interest to declare.
Publisher Copyright:
© Europa Digital & Publishing 2021. All rights reserved.
PY - 2021/8
Y1 - 2021/8
N2 - Background: In-stent restenosis (ISR) is highly prevalent and leads to repeat revascularisation. Long-term implications of ISR are poorly understood. Aims: This study aimed to evaluate the long-term outcomes of patients undergoing percutaneous coronary intervention (PCI) for ISR. Methods: National Cardiovascular Data Registry CathPCI records for individuals aged ≥65 years undergoing PCI from July 2009 to December 2014 were linked to Medicare claims. Baseline characteristics and long-term rates of death, myocardial infarction (MI), repeat revascularisation including target vessel revascularisation (TVR), and major adverse cardiovascular and cerebrovascular events (MACCE) were compared between ISR PCI versus de novo lesion PCI. Results: Of 653,304 individuals, 10.2% underwent ISR PCI and 89.8% underwent de novo lesion PCI. The median duration of follow-up was 825 days (quartile 1: 352 days-quartile 3: 1,379 days). The frequency of MACCE (55.6% vs 45.0%; p<0.001), all-cause mortality (27.8% vs 25.5%; p<0.001), MI (19.0% vs 12.3%; p<0.001), repeat revascularisation (31.9% vs 18.6%; p<0.001), TVR (22.4% vs 8.0%; p<0.001), and stroke (8.8% vs 8.3%; p=0.005) was higher after ISR PCI. After multivariable adjustment, ISR PCI remained associated with worse long-term outcomes than after de novo lesion PCI (hazard ratio [HR] for MACCE 1.24 [95% CI: 1.22, 1.26], mortality 1.07 [95% CI: 1.05, 1.09], MI 1.44 [95% CI: 1.40, 1.48], repeat revascularisation 1.55 [95% CI: 1.51, 1.59], and TVR 2.50 [95% CI: 2.42, 2.58]). Conclusions: ISR PCI was common and was associated with a significantly higher risk of recurrent long-term major ischaemic events compared to patients undergoing de novo lesion PCI. There remains a need for new strategies to minimise ISR.
AB - Background: In-stent restenosis (ISR) is highly prevalent and leads to repeat revascularisation. Long-term implications of ISR are poorly understood. Aims: This study aimed to evaluate the long-term outcomes of patients undergoing percutaneous coronary intervention (PCI) for ISR. Methods: National Cardiovascular Data Registry CathPCI records for individuals aged ≥65 years undergoing PCI from July 2009 to December 2014 were linked to Medicare claims. Baseline characteristics and long-term rates of death, myocardial infarction (MI), repeat revascularisation including target vessel revascularisation (TVR), and major adverse cardiovascular and cerebrovascular events (MACCE) were compared between ISR PCI versus de novo lesion PCI. Results: Of 653,304 individuals, 10.2% underwent ISR PCI and 89.8% underwent de novo lesion PCI. The median duration of follow-up was 825 days (quartile 1: 352 days-quartile 3: 1,379 days). The frequency of MACCE (55.6% vs 45.0%; p<0.001), all-cause mortality (27.8% vs 25.5%; p<0.001), MI (19.0% vs 12.3%; p<0.001), repeat revascularisation (31.9% vs 18.6%; p<0.001), TVR (22.4% vs 8.0%; p<0.001), and stroke (8.8% vs 8.3%; p=0.005) was higher after ISR PCI. After multivariable adjustment, ISR PCI remained associated with worse long-term outcomes than after de novo lesion PCI (hazard ratio [HR] for MACCE 1.24 [95% CI: 1.22, 1.26], mortality 1.07 [95% CI: 1.05, 1.09], MI 1.44 [95% CI: 1.40, 1.48], repeat revascularisation 1.55 [95% CI: 1.51, 1.59], and TVR 2.50 [95% CI: 2.42, 2.58]). Conclusions: ISR PCI was common and was associated with a significantly higher risk of recurrent long-term major ischaemic events compared to patients undergoing de novo lesion PCI. There remains a need for new strategies to minimise ISR.
KW - Death
KW - In-stent restenosis
KW - Myocardial infarction
KW - Prior PCI
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=85100456554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100456554&partnerID=8YFLogxK
U2 - 10.4244/EIJ-D-19-01031
DO - 10.4244/EIJ-D-19-01031
M3 - Article
C2 - 32863243
AN - SCOPUS:85100456554
SN - 1774-024X
VL - 17
SP - 380
EP - 387
JO - EuroIntervention
JF - EuroIntervention
IS - 5
ER -